AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36201995 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral strengths
Number of subjects: 137
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anaemia (Hb 4-6 g/dL and no severity features), no transfusion during initial admission
Number of subjects: 3894
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 3894
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 hospital admissions in the preceding 12 months
Number of subjects: 3894
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: History of transfusion
Number of subjects: 3894
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing ≥1 trial medication dose
Number of subjects: 3894
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria (among children with no prior history of transfusion)
Number of subjects: 3894
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 3894
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: Known sickle cell disease
Number of subjects: 3894
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross splenomegaly
Number of subjects: 3894
Study 34325680 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlarged spleen
Number of subjects: 3894
Study 35311593 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg shrimp oil once per day for eight weeks
Number of subjects: 64
Study 35311593 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo containing medium-chain triglycerides
Number of subjects: 64
Study 35387677 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador M
Number of subjects: 45
Study 35387677 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador P
Number of subjects: 45
Study 35387677 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 45
Study 35598698 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 0
Study 35598698 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating interval
Number of subjects: 0
Study 35598698 — intervention group
Group type: EXPERIMENTAL
Intervention: First meal timing variation
Number of subjects: 0
Study 35598698 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular first meal timing
Number of subjects: 0
Study 35598698 — intervention group
Group type: EXPERIMENTAL
Intervention: Last meal timing
Number of subjects: 0
Study 35598698 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to 50% daily calorie intake
Number of subjects: 0
Study 34941541 — intervention group
Group type: EXPERIMENTAL
Intervention: iSMI GET.ON Stress (7 sessions + 1 booster session, no therapeutic guidance)
Number of subjects: 396
Study 34941541 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (6-month waiting period)
Number of subjects: 396
Study 34941541 — intervention group
Group type: EXPERIMENTAL
Intervention: iSMI GET.ON Stress
Number of subjects: 396
Study 34965763 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-pilot US-guided technique
Number of subjects: 51
Study 34965763 — intervention group
Group type: COMPARATOR
Intervention: Standard US guidance
Number of subjects: 51
Study 33713215 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI)
Number of subjects: 145
Study 33713215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 34624248 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month followed by 2-month placebo (Group A)
Number of subjects: 252
Study 34624248 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 months followed by 1-month placebo (Group B)
Number of subjects: 252
Study 34624248 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months (Group C)
Number of subjects: 252
Study 34624248 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 252
Study 33423209 — intervention group
Group type: COMPARATOR
Intervention: Caries experience-free children
Number of subjects: 3702
Study 33423209 — intervention group
Group type: COMPARATOR
Intervention: Initial caries lesions (ICDAS1-2)
Number of subjects: 3702
Study 33423209 — intervention group
Group type: COMPARATOR
Intervention: Mean d1-2t/D1-2T
Number of subjects: 3702
Study 33423209 — intervention group
Group type: COMPARATOR
Intervention: Mean d3-6mft/D3-6MFT
Number of subjects: 3702
Study 33423209 — intervention group
Group type: COMPARATOR
Intervention: Caries experience related to socio-demographic factors
Number of subjects: 3702
Study 33423209 — intervention group
Group type: COMPARATOR
Intervention: Initial caries lesions probability
Number of subjects: 3702
Study 33423209 — intervention group
Group type: COMPARATOR
Intervention: Caries prevalence and experience levels over ten years
Number of subjects: 3702
Study 34935707 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 38
Study 34935707 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 38
Study 33188696 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive illness perceptions
Number of subjects: 1087
Study 33188696 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvers (switched from negative to positive illness perceptions)
Number of subjects: 1087
Study 33188696 — intervention group
Group type: COMPARATOR
Intervention: Negative illness perceptions
Number of subjects: 1087
Study 34826525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic descriptive social norm message displayed during the first two weeks of the study period
Number of subjects: 22
Study 34826525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic descriptive social norm message displayed during the last two weeks of the study period
Number of subjects: 22
Study 34826525 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity stores with the intervention
Number of subjects: 22
Study 32788318 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-handed C-E technique
Number of subjects: 74
Study 32788318 — intervention group
Group type: COMPARATOR
Intervention: 2-handed V-E technique
Number of subjects: 74
Study 32788318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 74
Study 34952104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of Strength program (intervention group)
Number of subjects: 1633
Study 34952104 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition (control group)
Number of subjects: 1633
Study 37584047 — intervention group
Group type: EXPERIMENTAL
Intervention: Early structured mobilisation protocol within 3 days of hospital admission till discharge
Number of subjects: 30
Study 37584047 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual medical care only)
Number of subjects: 30
Study 32919068 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose eplerenone (100-200 mg)
Number of subjects: 140
Study 32919068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 32664953 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding enteral feeds for 12 hours from the start of transfusion
Number of subjects: 41
Study 32664953 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing enteral feeds during transfusion
Number of subjects: 41
Study 32664953 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of enteral feed volume to 120 ml/kg/day for 12 hours
Number of subjects: 41
Study 32664953 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 41
Study 35918311 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of dried psilocybin mushrooms
Number of subjects: 34
Study 35918311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32233985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretarsal Group: 5 units of onabotulinum toxin A injected into 2 points of the pretarsal portion
Number of subjects: 30
Study 32233985 — intervention group
Group type: COMPARATOR
Intervention: Preseptal Group: 5 units of onabotulinum toxin A injected into 4 points of the preseptal portion
Number of subjects: 30
Study 32176761 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sausage rich in animal fat (mortadella)
Number of subjects: 8
Study 32176761 — intervention group
Group type: COMPARATOR
Intervention: Modified product based on a plant-derived fat analogue and an aroma
Number of subjects: 8
Study 616564354 — intervention group
Group type: EXPERIMENTAL
Intervention: 50%LBY
Number of subjects: 16
Study 616564354 — intervention group
Group type: COMPARATOR
Intervention: 0:0:100 (RS)
Number of subjects: 16
Study 616564354 — intervention group
Group type: COMPARATOR
Intervention: 0:70:30 (0%LBY)
Number of subjects: 16
Study 616564354 — intervention group
Group type: COMPARATOR
Intervention: 20:50:30 (20%LBY)
Number of subjects: 16
Study 616564354 — intervention group
Group type: COMPARATOR
Intervention: 50:20:30 (50%LBY)
Number of subjects: 16
Study 35998623 — intervention group
Group type: EXPERIMENTAL
Intervention: SOBERANA 02 (two doses) + SOBERANA Plus (third dose)
Number of subjects: 810
Study 35998623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 810
Study 34310011 — intervention group
Group type: EXPERIMENTAL
Intervention: ORMD-0801 (16 or 24 mg, once daily at bedtime for 28 days)
Number of subjects: 188
Study 34310011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 33655801 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment in the trial (n=40)
Number of subjects: 90
Study 33655801 — intervention group
Group type: COMPARATOR
Intervention: Declined enrollment (n=50)
Number of subjects: 90
Study 34189703 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2586881 0.8 mg/kg
Number of subjects: 17
Study 34189703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 34783100 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) prescribed if blood eosinophils ≥3%
Number of subjects: 60
Study 34783100 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted antibiotics for airway bacterial infection
Number of subjects: 60
Study 34783100 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 33150711 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 180
Study 33150711 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 180
Study 33150711 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser acupuncture
Number of subjects: 180
Study 34767488 — intervention group
Group type: EXPERIMENTAL
Intervention: Independently getting off the floor (IGO) technique
Number of subjects: 17
Study 32049923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% estriol vaginal gel
Number of subjects: 61
Study 32049923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 34043000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 223
Study 32894700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat tissue grafts (group A)
Number of subjects: 140
Study 32894700 — intervention group
Group type: COMPARATOR
Intervention: Areolar tissue grafts (group B)
Number of subjects: 140
Study 33982797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-containing beetroot juice
Number of subjects: 93
Study 33982797 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 93
Study 33982797 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 93
Study 33982797 — intervention group
Group type: COMPARATOR
Intervention: Placebo nitrate-depleted juice
Number of subjects: 93
Study 32929822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led, patient-oriented education and medication management intervention
Number of subjects: 116
Study 32929822 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study 35335942 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet Nebulizer with Valved Holding Chamber (JN + VHC)
Number of subjects: 7
Study 32014275 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage surgery (n=78 out of 91 willing patients)
Number of subjects: 113
Study 32014275 — intervention group
Group type: COMPARATOR
Intervention: No salvage surgery (n=22 unwilling patients)
Number of subjects: 113
Study 34793586 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshest available blood (mean age of blood units: 11 days)
Number of subjects: 14461
Study 34793586 — intervention group
Group type: COMPARATOR
Intervention: Oldest available blood (mean age of blood units: 23 days)
Number of subjects: 14461
Study 34793586 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood age as a continuous variable (duration of storage in days)
Number of subjects: 14461
Study 34881943 — intervention group
Group type: EXPERIMENTAL
Intervention: Duchenne smile
Number of subjects: 231
Study 34881943 — intervention group
Group type: EXPERIMENTAL
Intervention: Grimace
Number of subjects: 231
Study 34881943 — intervention group
Group type: COMPARATOR
Intervention: Neutral expression
Number of subjects: 231
Study 35453122 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitask Training (MTT)
Number of subjects: 42
Study 35453122 — intervention group
Group type: COMPARATOR
Intervention: Multicomponent Training (MCT)
Number of subjects: 42
Study 33849913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2,000 IU orally daily for 1 year)
Number of subjects: 300
Study 33849913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 35680252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis products added to a behavioural pain management and prescription opioid taper support programme
Number of subjects: 250
Study 35680252 — intervention group
Group type: COMPARATOR
Intervention: Abstinence from cannabis use
Number of subjects: 250
Study 36395262 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% potassium oxalate (GPO) for 10 min
Number of subjects: 50
Study 36395262 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (GP)
Number of subjects: 50
Study 33218539 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 18
Study 36252745 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg daily from the day of surgery to postoperative day 6)
Number of subjects: 67
Study 36252745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 34404842 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 101
Study 34404842 — intervention group
Group type: COMPARATOR
Intervention: Standard care (silver‐impregnated dressings)
Number of subjects: 101
Study 32100500 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat-grain moxibustion at Yinbai (SP 1), performed once a day with an interval of 1 day between two 3-day treatments.
Number of subjects: 54
Study 32100500 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of dydrogesterone tablet, 10 mg twice a day.
Number of subjects: 54
Study 35180298 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (500mg or 1000mg 6-hourly for 72 hours)
Number of subjects: 396
Study 35569002 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol (OM) 50 µg four hourly for 48 hours
Number of subjects: 144
Study 35569002 — intervention group
Group type: COMPARATOR
Intervention: Supra cervical Foley catheter for 48 hours
Number of subjects: 144
Study 35063969 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401
Study 35063969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study 35063969 — intervention group
Group type: COMPARATOR
Intervention: Recalculation using the 2009 CKD-EPI equation without race-specific coefficient
Number of subjects: 4401
Study 35063969 — intervention group
Group type: COMPARATOR
Intervention: Recalculation using the 2021 CKD-EPI equation
Number of subjects: 4401
Study 35063969 — intervention group
Group type: COMPARATOR
Intervention: Recalculation using the 2009 equation
Number of subjects: 4401
Study 35063969 — intervention group
Group type: COMPARATOR
Intervention: Recalculation using the 2021 equation
Number of subjects: 4401
Study 34114522 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre (VM)
Number of subjects: 107
Study 34114522 — intervention group
Group type: COMPARATOR
Intervention: Tenaculum
Number of subjects: 107
Study 32871329 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization
Number of subjects: 840
Study 32871329 — intervention group
Group type: COMPARATOR
Intervention: Staged complete revascularization (within 19-45 days)
Number of subjects: 840
Study 34756180 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin
Number of subjects: 152
Study 34756180 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 152
Study 33588938 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Round Delphi
Number of subjects: 180
Study 33588938 — intervention group
Group type: COMPARATOR
Intervention: Real-Time Delphi
Number of subjects: 180
Study 32843372 — intervention group
Group type: EXPERIMENTAL
Intervention: Theranova 400 dialyzer
Number of subjects: 172
Study 32843372 — intervention group
Group type: COMPARATOR
Intervention: Elisio‐17H dialyzer
Number of subjects: 172
Study 36231179 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectations (SE+, OE+)
Number of subjects: 75
Study 36231179 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Efficacy positive (SE+)
Number of subjects: 75
Study 36231179 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome Expectations positive (OE+)
Number of subjects: 75
Study 36231179 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 75
Study 36231179 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Fatigue
Number of subjects: 75
Study 34052421 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaling + oral hygiene instructions
Number of subjects: 40
Study 34052421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling/oral hygiene instructions + aPDT
Number of subjects: 40
Study 32558469 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months.
Number of subjects: 1047
Study 32558469 — intervention group
Group type: COMPARATOR
Intervention: Guided treatment (screening with Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography).
Number of subjects: 1047
Study 32558469 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic treatment
Number of subjects: 1047
Study 32558469 — intervention group
Group type: COMPARATOR
Intervention: Guided treatment
Number of subjects: 1047
Study 35969436 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder group (daily reminders via WeChat)
Number of subjects: 716
Study 35969436 — intervention group
Group type: COMPARATOR
Intervention: No-reminder group (no reminders)
Number of subjects: 716
Study 35969436 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder group
Number of subjects: 716
Study 34533505 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) algorithm for predicting unplanned subsequent surgery after intramedullary nailing (IMN) for TSFs
Number of subjects: 1198
Study 35945566 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alteplase (5mg) followed by continuous IV infusion of m‐proUK (40 mg/h during 60 min)
Number of subjects: 200
Study 35945566 — intervention group
Group type: COMPARATOR
Intervention: Usual care with alteplase (0.9 mg/kg)
Number of subjects: 200
Study 33805908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin (TTX) 30 µg BID
Number of subjects: 125
Study 33805908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 35549912 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with high-dose mytomicin-C (35 mg/m2)
Number of subjects: 216
Study 35549912 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized systemic chemotherapy (both arms)
Number of subjects: 216
Study 35549912 — intervention group
Group type: COMPARATOR
Intervention: Control group (without HIPEC)
Number of subjects: 216
Study 32234275 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth delivery of the dyadic intervention program
Number of subjects: 63
Study 32234275 — intervention group
Group type: COMPARATOR
Intervention: Home visit delivery of the dyadic intervention program
Number of subjects: 63
Study 35688358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cross-over adjusted)
Number of subjects: 86
Study 34210228 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and DHA supplementation
Number of subjects: 84
Study 34210228 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 84
Study 32789809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim-cbqv
Number of subjects: 122
Study 32789809 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim
Number of subjects: 122
Study 35999163 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc
Number of subjects: 224
Study 35999163 — intervention group
Group type: COMPARATOR
Intervention: Rebamipide
Number of subjects: 224
Study 34956918 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine taken at dusk 30-min before Iftar meal (group 1)
Number of subjects: 148
Study 34956918 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine taken 3 or more hours after Iftar meal (group 2)
Number of subjects: 148
Study 34956918 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine taken at dawn 30-min before Suhur meal (group 3)
Number of subjects: 148
Study 32658298 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT delivered via telemedicine (CBT-TM)
Number of subjects: 65
Study 32658298 — intervention group
Group type: COMPARATOR
Intervention: CBT delivered face-to-face (CBT-F2F)
Number of subjects: 65
Study 32019699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automatic, deep learning‐based segmentation algorithm
Number of subjects: 62
Study 32019699 — intervention group
Group type: COMPARATOR
Intervention: Semiautomatic measurements by expert readers
Number of subjects: 62
Study 36209381 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of triamcinolone acetonide after fractional CO2 laser treatment
Number of subjects: 30